Antes

Pharma Tech

Astellas Pharma Inc. | September 30, 2022

Astellas Pharma Inc. announced the European Medicines Agency has accepted for regulatory review the company's marketing authorization application for fezolinetant, an investigational oral, nonhormonal compound seeking approval for the treatment of moderate to severe vasomotor symptoms associated with menopause. VMS, characterized by hot flashes and/or night sweats, are common symptoms of menopause.1,2 "More than half of women 40 to 64 years of age ex...

Business Insights

Replica Analytics | June 30, 2022

Critical Path Institute and Replica Analytics, an Aetion company, announced a new partnership that involves leveraging synthetic data to further catalyze the generation of actionable solutions to accelerate drug development for rare diseases. Replica Analytics will help generate synthetic datasets across rare and orphan indications in which patient-level datasets are often quite small, which heightens considerations regarding data privacy and accessibility. Together...

Fiercepharma | May 05, 2020

Alexion has made no secret of its plan to diversify beyond its blockbuster rare disease franchise. Now, the company has taken a flier out on a disappointing drug that targets severe bleeding—and it's hoping to parlay its hospital contacts into a sales boost that'll appease unruly investors. Alexion agreed to buy Portola Pharmaceuticals and its sole approved medicine, anticoagulant reversal agent Andexxa, in a deal valued at around $1.4 billion, the drugmakers said Monday. That'...

DECK 7 | February 04, 2020

Demand owns content, and with the release of 'Salesforce CMS', it’s clear that Salesforce is putting the control squarely with demand, not to mention delighting the creative marketer with more power through additional tools for creating content that are expected to work well right out of the box (er… cloud). Customers have become accustomed to consuming content across multiple channels and platforms which requires marketers to provide for seamless integration of their conten...